Glucocorticoid_NN
receptors_NNS
are_VBP
down-regulated_VBN
in_IN
inflamed_JJ
colonic_JJ
mucosa_NN
but_CC
not_RB
in_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
from_IN
patients_NNS
with_IN
inflammatory_JJ
bowel_NN
disease_NN
-LCB-_-LRB-
see_VB
comments_NNS
-RCB-_-RRB-

BACKGROUND_NN
:_:
Growing_VBG
evidence_NN
indicates_VBZ
that_IN
the_DT
immune_JJ
system_NN
and_CC
the_DT
hypothalamic-pituitary-adrenal_JJ
system_NN
are_VBP
linked_VBN
by_IN
several_JJ
mechanisms_NNS
,_,
for_IN
example_NN
intracellular_JJ
glucocorticoid_NN
receptors_NNS
-LRB-_-LRB-
hGR_NN
-RRB-_-RRB-
._.

Glucocorticoids_NNS
are_VBP
the_DT
standard_JJ
treatment_NN
of_IN
acute_JJ
attacks_NNS
of_IN
inflammatory_JJ
bowel_NN
disease_NN
-LRB-_-LRB-
IBD_NN
-RRB-_-RRB-
._.

Binding_NN
of_IN
glucocorticoids_NNS
to_TO
hGR_NN
down-regulates_VBZ
the_DT
transcription_NN
of_IN
inflammatory_JJ
genes_NNS
that_WDT
can_MD
propagate_VB
IBD_NN
._.

PATIENTS_NNS
AND_CC
METHODS_NNS
:_:
IBD_NN
patients_NNS
were_VBD
either_RB
treated_VBN
with_IN
5-60_CD
mg_NN
of_IN
prednisolone_NN
for_IN
more_JJR
than_IN
1_CD
week_NN
or_CC
were_VBD
without_IN
glucocorticoid_NN
treatment_NN
for_IN
more_JJR
than_IN
4_CD
weeks_NNS
._.

hGR_NN
levels_NNS
were_VBD
determined_VBN
from_IN
isolated_VBN
cytosol_NN
of_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMCs_NNS
-RRB-_-RRB-
or_CC
mucosal_JJ
biopsies_NNS
using_VBG
a_DT
radioassay_NN
with_IN
-LCB-_-LRB-
3H-RCB_CD
--_:
dexamethasone_NN
._.

Interleukin_NN
-LRB-_-LRB-
IL_NN
-RRB-_-RRB-
6_CD
levels_NNS
were_VBD
determined_VBN
by_IN
enzyme-linked_JJ
immunosorbent_JJ
assay_NN
-LRB-_-LRB-
ELISA_NN
-RRB-_-RRB-
._.

RESULTS_NNS
:_:
The_DT
systemic_JJ
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
hGR_NN
levels_NNS
of_IN
corticosteroid-treated_JJ
IBD_NN
patients_NNS
were_VBD
significantly_RB
lower_JJR
than_IN
those_DT
of_IN
control_JJ
subjects_NNS
-LRB-_-LRB-
59.6_CD
+_CC
\/_NN
-_:
57.1_CD
dpm_NN
mg-1_NN
cytosol_NN
protein_NN
vs._CC
227.0_CD
+_CC
\/_CD
-_:
90.8_CD
dpm_NN
mg-1_NN
cytosol_NN
protein_NN
,_,
P_NN
=_JJ
0.007_CD
-RRB-_-RRB-
and_CC
IBD_NN
patients_NNS
not_RB
receiving_VBG
glucocorticoid_NN
treatment_NN
-LRB-_-LRB-
179.7_CD
+_CC
\/_CD
-_:
171.3_CD
dpm_NN
mg-1_NN
cytosol_NN
protein_NN
,_,
P_NN
=_JJ
0.002_CD
-RRB-_-RRB-
._.

Systemic_JJ
hGR_NN
levels_NNS
in_IN
untreated_JJ
IBD_NN
patients_NNS
did_VBD
not_RB
differ_VB
significantly_RB
from_IN
those_DT
in_IN
control_NN
subjects_NNS
._.

In_IN
patients_NNS
with_IN
connective_JJ
tissue_NN
diseases_NNS
,_,
systemic_JJ
hGR_NN
levels_NNS
were_VBD
also_RB
found_VBN
to_TO
be_VB
decreased_VBN
in_IN
the_DT
absence_NN
of_IN
glucocorticoid_NN
treatment_NN
._.

Systemic_JJ
hGR_NN
levels_NNS
in_IN
patients_NNS
with_IN
Crohn_NN
's_POS
disease_NN
-LRB-_-LRB-
CD_NN
-RRB-_-RRB-
treated_VBN
with_IN
steroids_NNS
-LRB-_-LRB-
66.6_CD
+_CC
\/_CD
-_:
61.0_CD
dpm_NN
mg-1_NN
cytosol_NN
protein_NN
-RRB-_-RRB-
were_VBD
not_RB
different_JJ
from_IN
those_DT
in_IN
patients_NNS
with_IN
ulcerative_JJ
colitis_NN
-LRB-_-LRB-
UC_NN
-RRB-_-RRB-
-LRB-_-LRB-
56.1_CD
+_CC
\/_CD
-_:
51.6_CD
dpm_NN
mg-1_NN
cytosol_NN
protein_NN
-RRB-_-RRB-
._.

In_IN
contrast_NN
to_TO
these_DT
findings_NNS
,_,
mucosal_JJ
hGR_NN
levels_NNS
were_VBD
significantly_RB
decreased_VBN
in_IN
both_CC
steroid-treated_JJ
-LRB-_-LRB-
18.0_CD
+_CC
\/_CD
-_:
15.5_CD
-RRB-_-RRB-
and_CC
not_RB
steroid-treated_JJ
-LRB-_-LRB-
37.8_CD
+_CC
\/_CD
-_:
30.5_CD
-RRB-_-RRB-
patients_NNS
compared_VBN
with_IN
control_JJ
subjects_NNS
-LRB-_-LRB-
125.6_CD
+_CC
\/_CD
-_TO
97.1_CD
;_:
P_NN
=_JJ
0.00009_CD
and_CC
P_NN
=_JJ
0.0008_CD
respectively_RB
-RRB-_-RRB-
._.

IL-6_NN
levels_NNS
in_IN
all_DT
IBD_NN
groups_NNS
with_IN
and_CC
without_IN
steroids_NNS
were_VBD
significantly_RB
different_JJ
from_IN
those_DT
in_IN
control_NN
subjects_NNS
._.

CONCLUSION_NN
:_:
In_IN
IBD_NN
there_EX
is_VBZ
no_DT
difference_NN
in_IN
systemic_JJ
hGR_NN
levels_NNS
between_IN
not_RB
steroid-treated_JJ
patients_NNS
and_CC
control_JJ
subjects_NNS
,_,
in_IN
spite_NN
of_IN
inflammatory_JJ
activity_NN
-LRB-_-LRB-
IL-6_NN
-RRB-_-RRB-
._.

Mucosal_JJ
hGR_NN
levels_NNS
were_VBD
decreased_VBN
independently_RB
of_IN
treatment_NN
,_,
probably_RB
leading_VBG
to_TO
a_DT
decreased_VBN
protection_NN
against_IN
NF-kappaB_NN
action_NN
in_IN
the_DT
intestinal_JJ
mucosa_NN
._.

